Method for collecting bacteriophage in incubation period based on nano-coating and application
By forming polymer nanocoated layers on bacterial cells, the problem of phages being easily damaged in the external environment is solved, and efficient phage treatment that is selectively released in the intestinal environment is achieved, which significantly improves the treatment of intestinal infections and the effects of arthritis.
Patent Information
- Application Number
- CN202411164321.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-29
AI Technical Summary
Phages are prone to impairment during amplification, purification and storage, resulting in reduced efficacy, especially in the gastrointestinal environment, which affects the effectiveness of oral phages in the treatment of intestinal infections.
Nanocoating technology is used to coat latent phages. By forming polymer nanocoating on bacterial cells, the phages are protected from the influence of the external environment and are selectively released when the intestinal pH value changes, maintaining the integrity and vitality of the phages.
It significantly improves the bioavailability and therapeutic effect of phages, enhances the efficacy of intestinal infections and arthritis, and provides an alternative nanoplatform to improve the stability and efficiency of phage therapy.
Smart Images

Figure CN119040275A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for collecting latent phages based on a nano coating and application thereof, belonging to the technical field of biomedicine. Background Art
[0002] Bacteriophages, especially lytic phages, have the specificity to effectively kill pathogenic bacteria. With the increase of antibiotic resistance, phage therapy has received extensive attention in the past few decades. In recent years, the number of clinical trials for phage therapy for various bacterial infections and related diseases (such as infectious enteritis, bacterial pneumonia and urinary tract infection) has increased. Maintaining phage activity during amplification, purification and storage is crucial to ensure antibacterial effect. However, phage activity is easily affected by the external environment. After being released from the host bacterial cells, its integrity is easily damaged. It has been reported that phage titers generally decrease when phages are incubated in typical culture media (including normal saline, phosphate buffer, Hartmann's solution and 5% glucose). The use of centrifugation during purification can also lead to a reduction in phage activity by several orders of magnitude, which also often occurs during phage storage. The reduction in phage activity is mainly attributed to the fact that its unique protein coat structure is easily denatured or degraded under environmental conditions. Unfortunately, clinical trials have shown that the reduction in phage activity significantly affects the efficacy of phage therapy. There is evidence that a clinical trial using a mixture of phages to treat burn wounds infected with Pseudomonas aeruginosa failed due to the instability of the prepared phages themselves. In this case, the titer of the phage preparation decreased by 1000-fold within 15 days of manufacture, resulting in the actual phage dose administered being far below the standard level. To address this challenge, various different formulations have been developed, such as microencapsulation of phages with pH-responsive polymers to protect phages from harsh environments. Although these methods have achieved certain success, since released phages are usually used, their structure is usually damaged and their activity is weakened.
[0003] After recognizing and injecting genes into the bacterial host, lytic phages use components of the infected bacterial host cell for DNA replication, mRNA translation, and protein synthesis. After the assembly of new phages is complete, lysis of the infected bacterial cell is induced by holin-endolysin, which then initiates the release of the newly generated latent phages. Once released into the external environment, the integrity of these intact phages is inevitably compromised. Therefore, it is speculated that the viability of latent phages is higher than that of phages that are attacked by external factors after being released from the host bacterial cell. However, due to the lack of tools to obtain latent phages and the inevitable release of phages assembled internally under natural conditions, there are few reports on the viability of latent phages.
[0004] Intestinal infections are a common symptom that can lead to a variety of gastrointestinal and systemic diseases. Despite the precise and effective methods of using bacteriophages to kill pathogenic bacteria, oral phage therapy for intestinal infections remains challenging. This is because in addition to various insults related to the preparation process of phage preparations, the presence of harsh environments such as gastric juice and bile acids in the gastrointestinal tract may also lead to impaired activity of ingested phages. As has been noted, most phages are inactivated after a few minutes of exposure to gastric acid. Therefore, methods that can introduce sufficiently active phages in the intestine via oral administration are crucial for the treatment of intestinal infections. Summary of the invention
[0005] The purpose of the present invention is: in view of the deficiencies of the prior art, the present invention aims to provide a method and application of collecting latent phages based on nano-coating.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] The first aspect of the present invention provides a method for preparing latent phage based on nano-coating, comprising the following steps:
[0008] Step 1: The host bacteria are cultured and separated to obtain bacterial cells, and the bacterial cells are infected with bacteriophages in the culture medium to obtain cells infected with bacteriophages;
[0009] Step 2: Place cells infected with phage in a solution of Ca 2+ The nano-coating is formed by shaking and incubating in a solution of (as a cross-linking agent) and the nano-material, washing, and collecting the precipitate by centrifugation to obtain the latent phage coated with the nano-coating.
[0010] Preferably, the nanomaterial in step 2 is a polymer nanomaterial, and the Ca 2+ Provided by soluble calcium salts such as calcium chloride.
[0011] Preferably, in order to form a single nanocoating on each bacterial cell, when the bacterial cells are infected with bacteriophages in the culture medium in step 1, the multiplicity of infection is 100 and the infection time is 15 minutes.
[0012] The second aspect of the present invention provides the use of the method described in the first aspect of the present invention in preparing latent phages coated with a stimulus-responsive nano-coating, wherein the nano-material used in the application is a stimulus-responsive polymer.
[0013] Preferably, the stimulus responsive polymer is a pH responsive polymer.
[0014] Preferably, the pH responsive polymer is methacrylic acid-ethyl acrylate copolymer.
[0015] The third aspect of the present invention provides a method for preparing a latent phage that can be specifically released in the intestine, comprising the following steps:
[0016] Step 1: The host bacteria are cultured and separated to obtain bacterial cells, and the bacterial cells are infected with bacteriophages in the culture medium to obtain cells infected with bacteriophages;
[0017] Step 2: Phage-infected cells are incubated in a solution containing intestinal stimuli-responsive polymers and Ca 2+ The intestinal irritation-responsive polymer is incubated in a solution of 1% MgCl2O3 and 1% MgCl2O3 to form a nano-coating, washed, and centrifuged to collect the precipitate, thereby obtaining latent phages coated with the nano-coating; the intestinal irritation-responsive polymer is an enteric polymer and / or a polymer that responds to intestinal pH.
[0018] Preferably, the intestinal irritation responsive polymer is methacrylic acid-ethyl acrylate copolymer.
[0019] The fourth aspect of the present invention provides the use of the latent phage prepared by the method described in the first aspect of the present invention in the preparation of antibacterial products (biological preparations for killing bacteria). For example, the use of the latent Salmonella typhimurium phage, latent Pseudomonas aeruginosa phage, and latent Staphylococcus aureus prepared by the method described in the first aspect of the present invention in the preparation of corresponding anti-Salmonella typhimurium preparations, anti-Pseudomonas aeruginosa preparations, and anti-Staphylococcus aureus preparations.
[0020] The fifth aspect of the present invention provides the use of the latent phage prepared by the method described in the first aspect of the present invention in the preparation of a biological product (biological preparation) for treating pathogen infectious diseases and pathogen infection-related arthritis.
[0021] The sixth aspect of the present invention provides the use of the latent phage prepared by the method described in the first aspect of the present invention in the preparation of a biological product (biological preparation) for treating intestinal Salmonella infection and related arthritis, characterized in that the related arthritis refers to arthritis induced by intestinal Salmonella infection, and the latent phage is a (enteritis) Salmonella phage.
[0022] The present invention provides a method for collecting latent phages based on nanocoatings, which manipulates the lysis process of phage-infected bacteria through a single bacteria isolation nanotechnology ( Figure 1 a). In other words, a whole polymer nanocoating is formed on a single phage-infected bacterium to prevent the phage from being released into the external environment after bacterial lysis. At the same time, the nanocoating retains the internal microenvironment of the bacteria to maintain the integrity of the latent phage. The latent phage obtained by the present invention retains its natural ability in terms of adsorption, amplification and lysis of bacteria and removal of bacterial biofilm, which is far superior to the released phage ( Figure 1b); Further mechanism studies found that key proteins in the phage tail, including the carrying domain protein, the tail sheath protein and the lytic protein A, were severely degraded during the release process; The present invention discloses that compared with latent phages, the key proteins of released phages (including the carrying domain protein, the tail sheath protein and the lytic protein A) are severely degraded.
[0023] The present invention can selectively release latent phages from lysed host bacteria at sites of interest in the body by using responsive nanocoatings. As a verification, the present invention uses enteric nanocoatings, such as an enteric nanocoating constructed from Eudragit L100-55 (hereinafter referred to as L100-55, a copolymer of methacrylic acid and ethyl acrylate (1:1)), so that phage-infected bacteria can maintain their intact structure in the stomach, protecting the latent phages inside the bacteria from gastric acid. After entering the intestine, the pH in the intestinal cavity changes from acidic to neutral, triggering the in situ dissolution of the nanocoating, thereby releasing intact phages, which can effectively kill the target pathogens in the intestine. In two mouse intestinal infection models and related infectious arthritis models ( Figure 1 c), after oral administration, the pH-triggered release of latent phages in the intestine exhibited significantly improved phage bioavailability, thereby greatly enhancing the therapeutic effect compared with traditional phage therapy. In the post-antibiotic era, this invention provides new insights into phage activity and an alternative nanoplatform for phage therapy.
[0024] Terminology explanation:
[0025] Latent phages refer to phages that are newly assembled inside host bacteria and have not been released into the external environment.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] 1) The present invention uses single-bacteria nano-coating technology to coat the surface of phage-infected bacteria with a polymer nano-coating, thereby blocking the release of phages after bacterial lysis, while retaining the internal microenvironment of the bacteria to maintain the integrity of the phages; these isolated phages show excellent ability to adsorb, amplify and lyse bacteria and remove bacterial biofilms;
[0028] 2) The present invention can greatly improve the bioavailability of phages by releasing latent phages in a pH-responsive manner in the intestine after oral administration in a mouse intestinal infection model and an infectious arthritis model, and has achieved significant therapeutic effects compared to traditional phage therapy; these results indicate that the use of stimulus-responsive nanocoatings can achieve in situ release of latent phages at sites of interest in the body, thereby improving the efficacy of phages. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The technical principle of the present invention is demonstrated; a: blocking the release of phages from infected host bacteria and protecting phages from external invasion through single bacterial nanocoating technology, as well as the different effects of phages released into the external environment and latent phages on pathogens and related biofilms; b: Different mechanisms of releasing and isolating phages in the treatment of intestinal bacterial infections and related arthritis; drawn using BioRender.com.
[0030] Figure 2 In-phages obtained by nanocoating are shown; a: Confocal image of Salmonella expressing green fluorescent protein and Cy5.5-labeled phages after incubation for 10 minutes at a multiplicity of infection of 100; scale bar, 5 μm; b: Flow cytometry histogram corresponding to a; c: The number of phages released from host bacteria at a multiplicity of infection of 10; d: Confocal images of Salmonella expressing green fluorescent protein and Cy5.5-labeled phages at different time points of incubation; scale bar, 20 μm; e: Salmonella, Ex-pha Zeta potential of Ex-phages and In-phages; f: Confocal image of Salmonella infected with phages modified with nanocoatings; the nanocoatings were labeled with Cy3 and the phages were labeled with Cy5.5; scale bar, 10 μm; g: Transmission electron microscopy image of Salmonella, Ex-phages, and In-phages; the phages within the host bacteria are highlighted in the magnified view; scale bar, 5 μm (left) and 50 nm (right); data are expressed as mean ± SD (n = 3); p values were determined using a two-sided t-test; **p < 0.01.
[0031] Figure 3The figure shows the high activity of intact phages; ah shows the activity of N1 phage under different conditions; a: Titer changes of In-phages and Ex-phages in 10mM PBS at 37℃; b: Titer changes of In-phages after incubation in different culture media for a certain period of time; c: Titer changes of In-phages and Ex-phages in LB culture medium; d: Titer changes of In-phages and Ex-phages in SM buffer; e: Titer changes of In-phages and Ex-phages in physiological saline; f: Titer changes of In-phages and Ex-phages in 10mM PBS at 4℃; g: Titer changes of In-phages after incubation in 10mM PBS at 50℃ and 70℃ for a certain period of time; h: Titer changes of Ex-phages in 10mM Titer changes after incubation in PBS at 50℃ and 70℃ for a certain period of time; i: Titer changes of In-phages and Ex-phages of P. aeruginosa at 37℃; j: Titer changes of In-phages and Ex-phages of Staphylococcus aureus at 37℃; blue and brown represent In-phages and Ex-phages, respectively.
[0032] Figure 4 Figure 3 shows the ability of In-phages in binding, lysing bacteria and clearing bacterial biofilms; af: Bacterial binding and bactericidal activities of In-phages and Ex-phages against (a, b) Salmonella, (c, d) Pseudomonas aeruginosa and (e, f) Staphylococcus aureus, respectively. The number of adsorbed phages was measured at different MOIs (0.1, 0.01, 0.001) after 30 min of incubation with the corresponding bacteria, and the bacterial counts were calculated 30 min after infection with the corresponding bacteria at an MOI of 100; gh: Confocal images of Salmonella expressing GFP (green) forming biofilms after infection with (g) Cy5.5-labeled In-phages and (h) Ex-phages (red). Scale bar, 50 μm; ij: Salmonella after infection with (i) different concentrations of phages for 30 min and (j) 5 × 10 10 Semi-quantitative analysis of the remaining biomass of phages at the specified time points after infection with (k) different concentrations of phages for 30 min and (l) 5×10 4Semi-quantitative analysis of the remaining biomass of phages at CFU / mL concentration after the indicated time points; data are presented as mean ± SD (n = 3); p values were determined using a two-sided t-test; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, blue and brown dots represent In-phages and Ex-phages, respectively.
[0033] Figure 5 Demonstrated high in vivo activity of intact phage; a: 5×10 7 Typical IVIS images of samples taken at different time points after oral administration of PFU In-phages; b: corresponding fluorescence intensity of Cy3 and Cy5.5 (n=4); unit: radiation efficiency (p / sec / cm 2 / sr) / (μW / cm 2 ); Ethylene copolymer and phage were labeled with Cy3 and Cy5.5, respectively; c: 5×10 7 Representative IVIS images of Ex-phages and In-phages labeled with PFU Cy5.5; d: Results of the fluorescence intensity heat map of the gastrointestinal tract sampled 1 hour after oral administration of mice, which contained 5×10 7 PFU Cy5.5 labeled Ex-phages and In-phages (n=5); Unit: Radiation efficiency (p / sec / cm 2 / sr) / (μW / cm 2 ); e: the number of phages counted in the small intestine 1 hour after oral administration; f: the number of phages counted in the colon 1 hour after oral administration; outliers were identified and deleted by SPSS using the Tukey method; g: confocal images of colon sections stained with Alexa Fluor 633-ConA (red); scale bar, 150 μm; data are expressed as mean ± SD; p values were determined using a two-sided t-test; **p < 0.01, ***p < 0.001.
[0034] Figure 6The potential mechanism of the high activity of In-phages is shown; ad. Cryo-TEM characterization of phage tips: phage particles from (a) Ex-phages and (b) In-phages, scale bar, 20 nm; (c) magnified view of the tip structure and C3 symmetry features; scale bar, 10 nm; (d) side and top views of the 3D rendered tip structure, and the overlap of the tip structure between Ex-phages and In-phages; blue arrows indicate missing density; ef: protein level results in (e) heat map and (f) volcano plot of Ex-phages and In-phages (n=3). gi: (g) Comparative analysis of proteins containing a carrier domain, (h) tail sheath proteins and (i) lytic protein A; jq. Localization and comparative analysis of specific peptides in the corresponding proteins: (j) Ribbon representation of proteins containing a carrier domain, annotated peptide FDNIDDNIDALAPLR[36-50]; (k) Abundance of peptide FDNIDDNIDALAPLR[36-50] in In-phages and Ex-phages; (l) Ribbon representation of proteins containing a carrier domain, annotated peptide MSNKPTYVEVMR[1-12]; (m) Abundance of peptide MSNKPTYVEVMR[1-12] in In-phages and Ex-phages; (n) (o) Abundance of peptide VFAVLNQFR[482-490] in In-phages and Ex-phages; (p) Band representation of lysate protein A, annotated peptide AAMDSAHGDISSGDWVR[193-209]; (q) Abundance of peptide AAMDSAHGDISSGDWVR[193-209] in In-phages and Ex-phages; Data are expressed as mean ± SD; p values were determined using a two-sided t-test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
[0035] Figure 7 Demonstrated the therapeutic value of In-phages in the treatment of intestinal infections and associated arthritis; 5×10 5 Mice infected with CFU of Salmonella were given 0.2 mL of 10 mM PBS and 5 × 10 7PFU Pure-phages, Ex-phages, and In-phages were treated for 9 days, and the therapeutic effects were evaluated 24 h after treatment, counting (a) Salmonella and (b) live N1 phages in the small intestine; (c) H&E staining of the colon; black arrows indicate pathological damage to the muscular layer; scale bar, 250 μm; (d) counts of Salmonella in the blood; levels of inflammatory cytokines (e) IL-6 and (f) TNF-α in plasma; gk. was orally infected with 1×10 7 Mice infected with CFU of Salmonella were given 0.2 mL of 10 mM PBS and 5 × 10 7 PFU Pure-phages, Ex-phages, and In-phages were treated for 5 days, and the therapeutic effects were evaluated 24 h after treatment: (g) Typical micro-CT images of the palm area of mice; red arrows indicate lesions in the metacarpophalangeal joints; (h) anti-dsDNA antibody levels and (i) IL-17 levels in plasma; (j) Th17 percentage in spleen and (k) IgA in MLNs + Percentage of B cells; Outliers were identified and deleted using the Tukey method by SPSS; Data are expressed as mean ± SD (n = 6-9); p values were determined using one-way ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
[0036] Figure 8 The biosafety of In-phages is demonstrated; a: weight fluctuation of mice; be: (b) white blood cell count, (c) neutrophil count, (d) red blood cell count and (e) platelet count in blood; fh: (f) CKMB, (g) ALP and (h) BUN levels in serum; where CKMB, ALP and BUN represent creatine kinase isoenzymes, alkaline phosphatase and blood urea nitrogen, respectively; i: H&E staining of heart, liver, spleen, lung, kidney, ileum and colon; Scale bar: 100 μm; Data are expressed as mean ± SD (n = 5); p value was determined using one-way ANOVA; ns represents no significant difference.
[0037] Fig. 9 The preparation process of phage-infected bacteria is shown; a: growth curve of Salmonella infected with N1 phage at different MOIs; bd: bacterial counts at (b) MOI=1, (c) MOI=10 and (d) MOI=100 after 24 hours of co-incubation with N1 phage; data are expressed as mean ± SD (n=3); *p<0.05, ***p<0.001, ****p<0.0001.
[0038] Fig.10Characterization of bacterial coating; a: Representative TEM images of sections of Salmonella Typhimurium and Salmonella Typhimurium infected with copolymer-coated phages, scale bar, 500 nm, and the magnified image shows the nanocoating structure formed on the bacterial surface, scale bar, 100 nm; bc: Representative (b) histograms and (c) scatter plots of flow cytometry of Salmonella Typhimurium and Salmonella Typhimurium infected with copolymer-coated phages; d: The percentage of Salmonella Typhimurium infected with copolymer-coated phages after coating formation; e: Average fluorescence intensity of Salmonella Typhimurium and Salmonella Typhimurium infected with Cy3-labeled copolymer-coated phages.
[0039] Fig.11 Observation of Salmonella infected with nanocoating-modified phages is shown; ab: representative (a) SEM (scale bar, 500 nm) and (b) TEM (scale bar, 500 nm) images of infected Salmonella with or without nanocoating; c: confocal images of mCherry-expressing Salmonella infected with phages with or without nanocoating, scale bar, 5 μm, and the bacterial cell membrane was stained with FM1-43FX (green).
[0040] Fig.12 The proliferation of phages is shown, and phages were collected for spot assay after 0, 5, 7, 9, 11, 13, and 24 hours of incubation.
[0041] Fig.13 Shown are the adsorption rates of In-phages and Ex-phages in 10 mM PBS within 30 min; a-c. Three different phages were tested: (a) Salmonella phage, (b) Pseudomonas aeruginosa phage, and (c) Staphylococcus aureus phage.
[0042] Fig.14 The changes in phage concentration in the intestine over time are shown; ad: phage counts in (a) stomach, (b) ileum, (c) cecum, and (d) colon; eh: distribution of phages in different intestinal segments at (e) 30, (f) 60, (g) 150, and (h) 210 min after oral instillation; data are expressed as mean ± SD (n = 4).
[0043] Fig.15 The local resolution maps and the corresponding Fourier shell correlation curves are shown; a: Ex-phage The top structure of In-phage; b: The top structure.
[0044] Fig.16Phage proteomic analysis is shown; a: Schematic diagram of the phage proteomic analysis process; b: Sodium dodecyl sulfate polyacrylamide gel electrophoresis of In-phages and Ex-phages; The red dashed box indicates that the protein level in Ex-phages is lower compared with In-phages.
[0045] Fig.17 Proteomic analysis of In-phages and Ex-phages is shown; ab: (a) principal component analysis and (b) Venn diagram of Ex-phages and In-phages protein expression data; c: dot heat map of Ex-phages and In-phages proteins; d: co-occurrence network constructed according to the relative abundance of differentially expressed proteins between Ex-phages and In-phages; eg: comparative analysis of (e) DNA ligase, (f) DNA helicase and (g) ribonucleotide diphosphorylase; data are expressed as mean ± standard deviation (n = 3); p values were determined using a two-tailed t-test; *p < 0.05, **p < 0.01, ***p < 0.001.
[0046] Fig.18 Figure 3 shows the inhibitory effect of phages on Salmonella growth and colonization in the intestine; a: experimental design of the Salmonella infection animal study; b: bacterial counts in feces; c: confocal images of colon sections stained with Salmonella O antibody (green) and DAPI (blue); scale bar, 200 μm; d: phage levels in feces; e: phage abundance in the entire intestine at the end of treatment; data are expressed as mean ± SD (n = 5-6); p values were determined using one-way ANOVA; ****p < 0.0001.
[0047] Fig.19 Demonstrated therapeutic effects of In-phages on infection-related reactive arthritis; a: Digital mouse joint density heat map visualized by micro-CT; b: Micro-CT imaging of mouse ankle joint; c: H&E staining of digital mouse joint; Scale bar, 800 μm; Red arrows indicate lesions in finger joints.
[0048] Fig. 20 Pathological evaluation of the intestine is shown; a: H&E staining of colon tissue, scale bar, 100 μm; b: Immunohistochemical staining of MPO-positive cells in colon tissue, MPO-positive cells appear in brown; scale bar, 200 μm.
[0049] Fig.21Shown are the effects of In-phages on the maintenance of the intestinal barrier; a: Evaluation of intestinal tight junction proteins, including ZO-1 and occludin, by fluorescence; b: AB-APS staining of colon sections; Scale bar, 200 μm.
[0050] Fig. 22 The experimental design of In-phages safety evaluation was presented. Healthy mice were orally administered 5×10 7 PFU of Pure-phages, Ex-phages and In-phages were added for 7 days, and as a control, 0.2 mL of 10 mM PBS was given.
[0051] Fig.23 Shown is the quantification of Salmonella in the intestine; a: images of agar plates with tissue samples from different intestinal segments; bc: bacterial counts in (b) ileum and (c) colon.
[0052] Fig.24 Routine blood tests and blood biochemical index levels are shown; ac: hematological indicators of whole blood (a) hemoglobin, (b) lymphocytes and (c) eosinophils; df: levels of (d) LDH, (e) AST and (f) CREA2 in plasma, LDH, AST and CREA2 represent lactate dehydrogenase, aspartate aminotransferase and creatinine, respectively, data are expressed as mean ± standard deviation (n = 5), p value was determined using one-way analysis of variance, ns indicates no significant difference. DETAILED DESCRIPTION
[0053] In order to make the present invention more clearly understood, preferred embodiments are described in detail below with reference to the accompanying drawings.
[0054] Unless otherwise specified, the experimental methods in the examples of the present invention for which specific conditions are not specified shall be selected according to conventional methods and conditions, or according to the product instructions; the strains, bacteriophages, reagents, instruments and equipment, experimental animals, etc. used in the examples of the present invention are conventional strains, bacteriophages, reagents, instruments and equipment, experimental animals in the field unless otherwise specified and are commercially available, animal experiments comply with the ethical requirements for experimental animals, and the acquisition and testing of human tissue samples comply with the requirements of medical ethics.
[0055] Some of the experimental methods involved in the embodiments of the present invention are as follows:
[0056] 1. Growth curves and counts of bacteria infected with phage at different MOIs
[0057] The growth dynamics of Salmonella labeled with red fluorescent protein were monitored every 15 minutes using a multifunctional microplate reader (Tecan Infinite M1000 PRO) at 580 nm excitation wavelength and 610 nm emission wavelength. 100 μL of Salmonella were infected with N1 phage (100 μL) at different infection multiplicity, including 1, 10 and 100. The phage and bacteria mixture was incubated at 37 ° C with a shaking speed of 200 rpm for 24 hours. Bacterial counts were measured at 0 hours and 24 hours, respectively.
[0058] 2. Collecting latent phage
[0059] Phage was added to 2 ml of Salmonella in the logarithmic growth phase using sterile LB medium (Sangon Biotech, catalog number A507003) with a multiplicity of infection of 10. The co-culture was incubated at 37°C for 15 minutes with gentle shaking at 200 rpm to promote viral infection. The cells were then precipitated by centrifugation at 13000 g for 30 seconds. The supernatant was then carefully sucked off to remove the unadsorbed phage. The precipitated cells were then resuspended in 1 ml of LB medium and then centrifuged to remove the supernatant. The washed cell pellet was finally resuspended in 2 ml of preheated LB medium and then incubated at 37°C with gentle shaking at 200 rpm. 50 microliters of culture were taken out at 0, 15, 20, 30, 40, 50, 60 and 70 minutes, and phage particles were quantified by double-layer agar plate method.
[0060] 3. Preparation of pure phages
[0061] The phage was purified according to the procedure described by Tiffany Luong et al. 1 ml of phage was mixed with 9 ml of Salmonella at a multiplicity of infection of 0.1 in LB medium. The co-culture was then incubated at 37°C with shaking at 200 rpm for 12 hours. The phage-bacteria co-culture was then centrifuged at 8000 g for 5 minutes to collect the supernatant. To remove bacteria, the supernatant was filtered twice through a 0.45 μm syringe filter. The filtered supernatant was then filtered again twice through a 0.22 μm syringe filter. The supernatant was then filtered through a 30 kDa molecular weight cutoff filter ( Catalog number UFC803096), replace LB medium with PBS (10 mM, pH 7.4) to prepare Pure-phages in PBS solution.
[0062] 4. Preparation of Ex-phages and In-phages
[0063] Salmonella was cultured in 4 ml of sterile LB medium (Sangon Biotech, catalog number A507003) with shaking at 37°C and 200rpm for 12 hours, and washed with PBS (10mM, pH 7.4) after centrifugation at 4000g for 5 minutes to obtain Salmonella cells. Then, cells (5×10^9CFU / mL) were infected with N1 phage at a multiplicity of infection of 100 in LB medium for 15 minutes. Phage-infected cells were washed twice in 10mM PBS (pH 7.4) and then suspended in 1 ml of ice-cold PBS (10mM, pH 7.4). The solution was vortexed at 25°C for 5 minutes and then washed 3 times with PBS (10mM, pH 7.4). Ex-phages were collected by centrifugation at 5,000g for 5 minutes. When preparing In-phages, 15 minutes after infection with phage at a multiplicity of infection of 100, the cells infected with phages were suspended in 1 ml of ice-cold PBS containing 12.5mM CaCl2 and 20mg / mL L100-55 solution (pH 6.76). The solution was shaken again for 5 minutes, and then centrifuged at 5,000g for 5 minutes after washing 3 times with 10mM PBS (pH 7.4). The sample was resuspended in 10mM PBS (pH 5.6). The formation of L100-55 nanocoating on bacteria infected with N1 phage was verified by morphological observation using a transmission electron microscope (TEM, HitachiHT7700), zeta potential measurement using a dynamic light scattering method (DLS, Zetasizer Nano ZS), and fluorescence imaging using a laser scanning microscope (LSCM, Nikon CSU-W1SoRa). After adding 3% chloroform, the sample was centrifuged at 3500g for 10 minutes. The supernatants were used to measure the assembly of In-phages at different time points including 0, 5, 7, 9, 11, 13, and 24 h.
[0064] 5. Transmission electron microscopy (TEM) observation
[0065] A drop of Ex-phages (Ex-phage) or In-phages (In-phage) solution was dropped on a carbon film-coated copper grid. After 15 minutes of deposition, the samples were washed twice with double distilled water (ddH2O) and completely dried in air. For the preparation of ultrathin sections, the bacteria or phage-infected bacteria solution (200 microliters) was washed three times with 10mM PBS (pH 7.4). Subsequently, the samples were fixed with 2.5% glutaraldehyde prepared in 0.1M phosphate buffer (pH 7.4) for 6 hours at 4°C. After rinsing with 0.1M phosphate buffer (4 times, 10 minutes each), they were post-fixed with 1% cadmium peroxide in phosphate buffer for 2 hours at room temperature and dehydrated using a gradient series of 30%, 50%, 70%, 90% and 100% ethanol (15 minutes each). Infiltration was performed using a mixture of propylene ether and resin in different volume ratios as follows: 100% propylene ether (2 times, 10 minutes each time), 1:1 propylene ether: resin (1 time, 2 hours), 1:2 propylene ether: resin (1 time, 2 hours), 1:3 propylene ether: resin (overnight). The samples were then embedded in fresh 100% resin in a flat mold and polymerized at 60°C for 48 hours. Ultrathin sections (80 nm) were prepared using a diamond knife on an ultramicrotome, placed on a copper grid, and stained with urocanthate uranyl and lead citrate in sequence. The morphology of bacteria and phages was observed using TEM (Hitachi HT7700) at 100 kV. Sample processing was performed at the Electron Microscopy Core Laboratory of the Shanghai Institute of Precision Medicine.
[0066] 6. Scanning Electron Microscope Observation
[0067] The solution (200 microliters) of Ex-phages or In-phages was washed 3 times with 10mM PBS (pH 7.4). Subsequently, the samples were fixed in 2.5% glutaraldehyde prepared in 0.1M phosphate buffer (PB, pH 7.4) for 6 hours at 4°C. Afterwards, rinsed with 0.1M PB (4 times, 10 minutes each time), and dehydrated with 30%, 50%, 70%, 90%, and 100% ethanol in gradually increasing concentrations (15 minutes each time). Next, 10 microliters of sample were placed on a silicon wafer and dried overnight in air at room temperature. Before being examined using a scanning electron microscope (HITACHI, Regulus 8230), the sample was subjected to gold spraying.
[0068] 7. Confocal Microscope Observation
[0069] The solution of Ex-phages or In-phages (200 μl) was washed three times with 10 mM PBS (pH 7.4). Subsequently, to stain the bacterial cell membrane, 5 μg / mL of FM1-43FX was added to the sample, incubated for 5 min, and then washed three times with PBS. The sample was centrifuged (3,500 g, 5 min) in PBS based on 4% formaldehyde fixative, and the bacteria were fixed at 4 °C for 2 h, washed three times in PBS, and then transferred to a sterile glass bottom dish for confocal microscopy imaging (Nikon CSU-W1SoRa).
[0070] 8. Fluorescent Dye Labeling of Phage and L100-55
[0071] Cy5.5 labeled phages were prepared by suspending the phages in 1 mg / mL Cy5.5-N-hydroxysuccinimide (NHS) solution (Duofluor, Cat no. D10013-1). For the labeling of Pure-phages, the Cy5.5-NHS solution was directly added to the phage solution (5×10^11 PFU / mL) and incubated at 4°C for 1 hour. The unreacted fluorescent dye was removed by ultrafiltration through a 30 kDa molecular weight cutoff filter. During the infection of the host bacteria, In-phages and Ex-phages were labeled by adding the dye (1 mg / mL). After incubation at room temperature with shaking at 1,000 rpm for 15 minutes, the reaction mixture was then centrifuged at 15,000g for 30 seconds and washed twice with PBS to remove the unreacted dye. To prepare Cy3-labeled L100-55, 1 mL of L100-55 (20 mg / mL) solution was incubated with 600 μL of 100 mg / mL 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) for 15 minutes to form an active ester intermediate. Subsequently, 90 μL of NHS (60 mg / mL) and 200 μL of Cy3-NH2 (5 mg / mL) were added to the reaction mixture, followed by ddH2O (1.9 mL) to reach the desired reaction concentration. After 24 hours of reaction, the solution was transferred to a dialysis bag with a molecular weight cutoff of 3,000-5,000 Da. The dialysis bag was then immersed in 1 L of ddH2O and dialyzed for 48 hours under stirring to remove unreacted Cy3-NH2.
[0072] 9. Detection of N1 phage infection of bacteria
[0073] GFP-labeled Salmonella typhimurium (Salmonella) was cultured in 4 mL LB medium at 37 ° C with shaking at 200 rpm for 12 hours. The bacterial culture (1 mL) was centrifuged at 5000 g for 5 minutes and washed 3 times with deionized water (ddH2O). The cells were then deposited on a glass-bottomed culture dish treated with poly-L-lysine (0.01 mg / mL) and incubated for 30 minutes. Unbound bacteria were removed by gently washing 6 times with 1 mL ddH2O. Subsequently, Cy5.5-labeled phage (5×10^11PFU / mL) was added to a culture dish containing 10 mM PBS. The interaction between phage and bacteria was observed by shooting every 2 minutes for 2 hours using a laser confocal microscope (LSCM, Nikon CSU-W1SoRa).
[0074] 10. The adsorption ratio of bacteriophage to host bacteria under different infection multiplicity conditions
[0075] Different strains (Salmonella typhimurium, Pseudomonas aeruginosa and Staphylococcus aureus) were cultured in 4 mL LB medium at 37 ° C with shaking at 200 rpm for 12 hours. Subsequently, bacterial cultures (1×10^9 CFU / mL) were exposed to specific phages at different infection multiplicities (0.1, 0.01 and 0.001). After 30 minutes of incubation, 400 μL of solution containing phages and bacteria was centrifuged at 21,000 g for 1 minute to collect the supernatant. Subsequently, the phage titer in the supernatant was determined by the double-layer agar plate method. The phage adsorption ratio was calculated by the following formula: phage adsorption rate (%) = (initial phage number-number of phages in the supernatant) / initial phage number.
[0076] 11. The adsorption rate of phage on host bacteria at a specific multiplicity of infection
[0077] In order to study the dynamics of phage infection, Salmonella typhimurium, Pseudomonas aeruginosa and Staphylococcus aureus (1×10^9CFU / mL) were mixed with specific phages (5×10^8PFU / mL) in LB medium. These co-cultures were shaken at 200rpm at 37°C for different time periods (0, 3, 4, 5, 15 and 30 minutes). The samples were then centrifuged at 21,000g for 1 minute to collect the supernatant. The phage counts in the supernatant were then measured by the double-layer agar plate method. The phage adsorption rate was calculated by the following formula: phage adsorption rate (%) = (initial phage count-phage count in supernatant) / initial phage count.
[0078] 12. Activity of Ex-phages and In-phages prepared under different conditions
[0079] Salmonella typhimurium, Pseudomonas aeruginosa and Staphylococcus aureus (5×10^9 CFU / mL) were cultured with phages at a multiplicity of infection of 100 at 37°C and 200rpm for 15 minutes in LB medium. Subsequently, the culture was aliquoted to prepare specific external phages and internal phages, respectively. The prepared external phages and internal phages were then resuspended in different sterile buffers of the same pH value, including 10mM phosphate buffer, 0.9% sodium chloride solution, LB medium and SM buffer. The external phages and internal phages were stored at 37°C in different solutions. In order to measure the effect of temperature on the activity of N1 phage, the prepared external phages and internal phages were stored at 4°C, 50°C and 70°C, respectively. The virus titer was then determined at predetermined time points by serial dilution and spot analysis.
[0080] 13. Efficacy of phage in removing biofilm
[0081] Bacteria (Salmonella typhimurium, Pseudomonas aeruginosa, and Staphylococcus aureus) were cultured in LB medium for 16 hours. Subsequently, 3% chloroform was added to the external phage and internal phage, and the solution was centrifuged at 8,000 g for 5 minutes to collect the supernatant. Next, ten-fold dilutions of the samples were prepared with fresh LB medium. (3879) 100 μL of diluted bacterial solution was added to the 96-well plate to start. The bacteria were cultured in the 96-well plate at 37°C for 48 hours. Next, the phage solution was diluted tenfold and added to each well. After incubation for a specific period of time, the plate was washed three times with 10 mM PBS (pH 7.4). Subsequently, 210 μL of 0.1% crystal violet was added to each well and incubated at room temperature for 40 minutes. The plate was then washed three times with 10 mM PBS (pH 7.4). Next, 210 μL of 30% acetic acid was added to release the stained biofilm in a microwell oscillator. Biomass was measured by testing the optical density at 540 nm.
[0082] 14. Cryo-TEM sample preparation and data collection
[0083] Three microliters of sample mixed with 10 nm colloidal gold fiducial markers were dropped onto glow-treated holey carbon grids (Quantifoil R1.2 / 1.3Cu, 300 mesh). After a 20-second incubation, the grids were dried for 1 second and quickly immersed in liquid ethane cooled by liquid nitrogen using a Vitrobot Mark IV (FEI) operated at 4°C and 100% humidity. Internal phage tomographic images, as well as all external phage tomographic images, were acquired using Tomography software (FEI) on a Talos Arctica (Thermo Fisher) equipped with a Falcon IV Summit direct electron detector, operating at 200 keV and at actual pixel size. In the case of , a nominal magnification of 73,000× was used. All tilt series (TS) were performed in dose fraction mode with an effective tilt range of -60° to 60°, a tilt increment of 3°, and a total dose of Acquired at a target defocus of -4 to -6 μm. Automated TS acquisition used a symmetric dose acquisition scheme and was aligned using fiducial markers via IMOD. Oblique images were aligned and contrast transfer function (CTF) correction was performed for oblique images using the “ctfphaseflip” function in IMOD. The aligned stacks with CTF correction were then tomographically imaged using TomoAlign using the Simultaneous Iterative Reconstruction Technique (SIRT).
[0084] 15. Subvolume averaging and related analysis process
[0085] Phage tips were manually picked from 4× downscaled tomographic images. Three-dimensional alignment and classification were performed using the i3 software package to obtain refined particle positions and eliminate useless particles. Class averages were calculated in Fourier space to minimize the missing wedge problem in tomographic images. Fourier shell coefficients were calculated by correlating two randomly split halves of the aligned images to estimate the resolution. Subsequently, the finely tuned particle positions were imported into TomoAlign and Relion for further structural refinement. A total of 193 subvolumes of the outer phage tip and 97 subvolumes of the inner phage tip were selected from the tomographic reconstruction for subvolume analysis. Local resolution variations were estimated using Relion. Surface rendering of subvolume averages was performed using UCSF ChimeraX.
[0086] 16. Protein extraction and digestion process
[0087] Proteins were extracted from N1 phage using sodium dodecyl sulfate and dithiothreitol (SDT) lysis buffer (4% sodium dodecyl sulfate, 100 mM dithiothreitol, 100 mM Tris-HCl, pH 8.0). The samples were then boiled and sonicated for 10 minutes. Undissolved cell debris was removed by centrifugation at 16,000 g for 15 minutes. The supernatant was used for protein quantification using a bicarboxylic acid (BCA) protein concentration assay kit. 200 μg of protein was digested using a filter-assisted sample preparation method. Briefly, organic solvents, dithiothreitol, and iodoacetamide were added to urea acetate buffer to block reduced cysteines. Finally, the protein suspension was digested overnight at 37°C with trypsin at a ratio of 50:1. The peptides were collected by centrifugation at 16,000 g for 15 minutes. The peptides were desalted by C18 StageTip for further liquid chromatography / mass spectrometry (LC / MS) analysis.
[0088] 17.LC-MS / MS analysis process
[0089] LC-MS / MS analysis was performed on a Q Exactive Plus mass spectrometer equipped with an Easy 1200nLC system (Thermo Fisher Scientific). First, the peptide mass was loaded into a trap column (100 μm × 20 mm, 5 μm, C18, Dr. Maisch HPLC GmbH) pre-wetted in buffer A (0.1% formic acid in water). The EASY-nLC system (Thermo Fisher Scientific) and a homemade column (75 μm × 150 mm; 3 μm, ReproSil-Pur C18 beads, Separation was performed by reverse phase high performance liquid chromatography (RP-HPLC) at a flow rate of 300 nL / min. The RP-HPLC mobile phase A was 0.1% formic acid in water and the mobile phase B was a mixture of 0.1% formic acid and 95% acetonitrile. The peptide mass was eluted over 120 min under the action of a linear gradient of buffer B. MS data were acquired using a data-dependent Top20 method with dynamic selection of the most abundant precursor ions from the excitation scan (300–1800 m / z) for high energy collision dissociation fragmentation. The instrument was operated in peptide recognition mode. A lock mass of 445.120025 Da was used as an internal standard for mass calibration. Full MS scans were acquired at a resolution of 70,000 at m / z 200 and MS / MS scans were acquired at a resolution of 17,500 at m / z 200. The maximum injection time was set to 50 ms for MS and 50 ms for MS / MS. The normalized collision energy was 27 eV. The isolation window was set to 1.6 Th. The duration of dynamic exclusion is 60 seconds.
[0090] 18.Sequence database search and data analysis
[0091] The raw LC-MS / MS data files were processed for database searching using the Sequest HT search engine in Proteome Discoverer 2.4 (Thermo Scientific). The UniProt Salmonella online database was used during protein identification. Label-free quantitative analysis was performed using Proteome Discoverer software to calculate relative protein abundance without labeling. For protein quantification, the data set was first screened to include only proteins with at least 3 valid values. Statistical analysis was then performed using R statistical computing software. Proteins with a change greater than 1.5-fold and a p-value less than 0.05 were considered to be significantly differentially expressed between conditions.
[0092] 19. Mouse Experiment
[0093] ICR mice and Balb / c mice were obtained from Shanghai Jiesijie Experimental Animal Co., Ltd. ICR mice were used to study the distribution of phages in the intestine, while Balb / c mice were used to evaluate the therapeutic value of In-phages in enteritis and arthritis caused by Salmonella typhimurium. Male mice aged 6-8 weeks were used in all in vivo experiments. Mice were housed in standard cages under standard conditions (12 h dark / 12 h light cycle; room temperature, 22 ± 2 °C; relative humidity, 55 ± 10%) and had free access to standard feed and drinking water. All animal experiments were performed in accordance with the guidelines evaluated and approved by the Laboratory Animal Welfare Ethics Committee of Shanghai Youshu Life Science (Shanghai) Co., Ltd.
[0094] 20. In vivo fluorescence imaging of bacteriophages
[0095] ICR mice (6-8 weeks old) were fasted for 12 h before the experiment. In-phages and Ex-phages labeled with Cy5.5 (5 × 10 7 PFU) were orally administered to mice in a single dose. In addition, L100-55 was labeled with Cy3. At the specified time points, mice were euthanized and the digestive tract was isolated. The fluorescence intensity of Cy5.5 in the intestine and the fluorescence distribution of Cy5.5 and Cy3 were evaluated using an in vivo imaging system (IVIS, PerkinElmer IVIS Lumina).
[0096] 21. Quantitative distribution of bacteriophages
[0097] ICR mice (6-8 weeks old) were acclimated for 1 week before the experiment. After fasting for 12 hours, the mice were orally given 5×10 3PFU / mL of In-phages or Ex-phages. At the indicated time intervals (30, 60, 150, and 210 min), mice were sacrificed by cervical dislocation under anesthesia. Then, the stomach, small intestine, colon, and cecum were isolated, weighed, and homogenized in 10 mM PBS. 100 μL of the sample was taken for phage culture on double-layer agar plates. After incubation at 37 °C overnight, the number of plaques was counted.
[0098] 22. Treatment of intestinal Salmonella infection in mice
[0099] The mouse model of Salmonella infection was established using male Balb / c mice aged 6-8 weeks. Mice were orally inoculated with 5×10 5 CFU Salmonella. 24 hours after infection, mice were gavaged daily with 10 mM PBS (phosphate buffered saline), pure phage (5×10 7 PFU), Ex-phages (5×10 7 PFU) and In-phages (5×10 7 PFU) for 9 days. During the treatment, 3-5 fecal specimens were collected daily for phage titer assessment. All mice were euthanized under anesthesia 24 hours after the last dose injection. Bacterial and phage counts in the blood, small intestine, and colon were measured separately. Serum was obtained by separating whole blood samples by centrifugation at 2,000g for 15 minutes at 4°C. The levels of IL-6 and TNF-α in serum were determined using enzyme-linked immunosorbent assay (ELISA) kits (Multi Sciences Biotech, Cat. no EK206 and EK282).
[0100] 23. Experimental study on the treatment of arthritis induced by intestinal Salmonella infection in mice
[0101] Experimental osteoarthritis was induced in male Balb / c mice aged 6-8 weeks. Mice were pretreated by oral administration of 20 mg streptomycin. After 24 h of antibiotic treatment, mice were orally administered 1×10 7 CFU of Salmonella. 24 hours after infection, mice were orally administered 200 μL 10 mM PBS, pure phage (5×10 7 PFU), Ex-phages (5×10 7 PFU) and In-phages (5×10 7PFU) for 5 days. On the 6th day after the initial infection, the mice were euthanized under anesthesia. The skeletal morphology of the mouse hind limbs was evaluated using micro-computed tomography (micro-CT) imaging. Serum was obtained by separating whole blood samples by centrifugation at 2,000g for 15 minutes at 4°C. According to the instructions of the ELISA kit (Mei Cotton, Cat.no MM-46291M1 and Multi Sciences Biotech, EK217), the levels of anti-dsDNA antibodies and IL-17 in serum were determined respectively. The frequency of IgA+B cells and Th17 cells was analyzed by flow cytometry.
[0102] 24. Safety Assessment of In-phages
[0103] Male Balb / c mice aged 6-8 weeks were acclimated for 1 week before the experiment. The mice were gavaged with 10 mM PBS, pure phage (5×10 7 PFU), Ex-phages (5×10 7 PFU) and In-phages (5×10 7 PFU) for 7 days. Then, the heart, liver, spleen, lung, kidney, ileum and colon were collected for H&E staining. At the same time, the ileum and colon were weighed and homogenized in 10mM PBS. A 100 μL sample was taken for Salmonella count. Blood samples were collected to measure hematology and blood biochemical parameters.
[0104] 25. Micro-computed tomography analysis of bone morphology in arthritis
[0105] Hindlimb bones were removed from euthanized mice and soft tissues were carefully removed. Bone samples were then fixed by immersion in 10% neutral buffered formaldehyde for 24 h. The fixed and dried samples were subsequently mounted vertically on custom holders for micro-CT scanning. High-resolution micro-computed tomography was performed on a Skyscan 1172 system at 50 kV and 200 μA. Approximately 700 projection images were acquired for each sample, covering 180° rotation, and reconstructed at an isometric voxel resolution of 5 μm. The reconstructed datasets were further analyzed using Skyscan CT-Analyser and DataViewer software. Three-dimensional renderings of the bone structure were generated, and locations of interest were selected to be marked, including the proximal and distal shafts of the femur and tibia, to observe changes in bone structure due to arthritis.
[0106] 26. Mucosal immune response
[0107] Mesenteric lymph nodes (MLNs) in the intestine were isolated. Next, the sample was passed through a 200-mesh nylon mesh filter to produce a single-cell suspension in PBS. The cells obtained (1 × 10 5Cells / mL) were first stained with extracellular antibodies for Th17 cells (CD3-APC-Cy7, CD4-FITC) and IgA+B cells (CD3-APC-Cy7, B220-PE-Cy7, PE-IgA). For staining of intracellular markers, the samples were then washed twice with PBS and fixed with fixation / permeabilization solution at 4°C overnight. After washing with 1×Perm / Was buffer, the cells were stained with intracellular antibody IL-17-Alexa Fluor 700. After two PBS rinses, the cells were resuspended with 300 μL PBS and measured by flow cytometry (BD LSRFortessa). The data were analyzed by FlowJo software (Tree Star Inc).
[0108] 27. Histopathology
[0109] Colon and ileum tissues were obtained from mice, dissected longitudinally after being rinsed in PBS, and fixed in wax overnight. The paws of mice were fixed with 10% formalin and then decalcified in 14% EDTA for 10 days. Paraffin was cut into 5 μm thick sections and stained with a hematoxylin-eosin (H&E) staining kit (Beyotime Biotechnology, Cat. No. C0105M). After defatting and dehydration, stain in hematoxylin staining solution for 10 minutes, followed by rinsing with running water for 10 minutes. Then treat with differentiation solution for 1 minute. After 10 minutes of running water rinsing, stain with istraxin staining solution for 2 minutes. To measure the thickness of the mucus layer, 5 μm thick sections were stained using an AB-PAS staining kit (MXT Biotechnology, Cat. No. MST-8005). Typically, tissue sections are stained with Alcian Blue (pH 2.5) staining solution for 10 minutes after soaking in acetic acid solution for 2 minutes. Then, the tissue sections are soaked in acetic acid solution for 2 minutes. After rinsing in tap water for 5 minutes, periodic acid solution was dropped into the tissue sections and incubated for 10 minutes. The tissue sections were stained with Schiff's solution for 15 minutes in the dark, followed by incubation with sodium bisulfite solution for 1 minute. The tissue sections were mounted with neutral balsam glue and imaged by a digital pathology scanner (Leica Biosystems Aperio CS2).
[0110] 28. Immunohistochemistry
[0111] 5 μm thick sections of colon were incubated in 3% H2O2 at room temperature for 10 min to block the activity of endogenous peroxidase. Then, citric acid antigen retrieval solution was added to the slides. The slides were incubated at 98°C for 10 min to visualize the antigen epitopes and rinsed twice with PBS. After blocking with 5% fetal bovine serum / PBS, the primary MPO antibody (1:250, Servicebio, Cat. No. GB11224) was incubated at 4°C overnight. After incubation with the corresponding secondary HRP antibody (1:200, Servicebio, Cat. No. G1215) at room temperature for 1 h, the samples were visualized by 3,3'-diaminobenzidine (DAB) substrate kit (Beyotime Biotechnology, Cat. No. P0203). MPO-positive (brown) cells were identified by a digital pathology scanner (Leica Biosystems Aperio CS2).
[0112] 29. Immunofluorescence staining
[0113] After defatting and dehydration, 5 μm thick sections of colon were incubated at 98°C for 20 min using 1× Universal High-Efficiency Antigen Retrieval Solution (Byotime, Cat. No. P0088). The sections were then stained with QuickBlock TM After incubation in blocking buffer (Byotime, Catalog No. P0260) for 30 minutes, primary antibodies including anti-ZO-1 (1:50, Affinity, Catalog No. AF5145) and anti-occludin (1:50, Occludin, Santa Cruz Biotechnology, Catalog No. sc-133256) were used for incubation overnight at 4°C. After washing three times with PBS, FITC-conjugated goat anti-rabbit IgG (1:300, Servicebio, Catalog No. GB22303) and Cy3-conjugated goat anti-mouse IgG (1:300, Servicebio, Catalog No. GB21301) secondary antibodies were added and incubated at room temperature for 1 hour. To measure biofilm, sections were stained with Alexa Fluor 633-ConA (1:50, Invitrogen, Catalog No. C21402). For bacterial detection, S. typhimurium O antibody (1:200, Bioss, cat. no. bs-8660R) and corresponding FITC-labeled secondary antibodies were used. The sections were mounted with anti-fading mounting medium containing 4',6-diamidino-2-benzylimidazole (DAPI). The obtained sections were imaged using LCSM (Nikon CSU-W1SoRa).
[0114] 30. Statistical analysis
[0115] SPSS software version 9.0.0 was used to perform unpaired two-tailed t-test for statistical comparisons between two independent groups. Multiple comparisons were performed by one-way analysis of variance (ANOVA) combined with Tukey's post-test. The significance of the difference: ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, indicating that there was a significant difference between the two groups.
[0116] Example 1: Formation of nanocoating on phage-infected bacteria
[0117] This example uses the N1 phage with Salmonella as the host bacterium isolated from a local hospital sewage sample as a model phage (reference: Meng, L. et al. Nanocapping-enabled charge reversalgenerates cell-enterable endosomal-escapable bacteriophages for intracellularpathogen inhibition. Sci Adv. 8, eabq2005 (2022)). The multiplicity of infection was studied to obtain the optimal conditions for forming a single nanocoating on each bacterial cell. The experimental results show that when the multiplicity of infection of Salmonella with N1 phage increased to 100, Salmonella continued to grow 24 hours after infection, but was completely inhibited under high multiplicity of infection conditions ( Fig. 9 ). 10 minutes after infection, the fluorescence signals between N1 phage labeled with Cy5.5 and Salmonella expressing green fluorescent egg overlapped, indicating that the host bacteria were almost completely infected by N1 phage ( Figure 2 a,b). As the co-culture time was extended to 40 minutes, the infected bacteria began to be lysed by the phage ( Figure 2 c, d). Therefore, under the condition of infection multiplicity of 100, Salmonella was co-cultured with N1 phage for 15 minutes to form a nanocoating, ensuring that each coated bacterial cell was infected but not lysed and phage released. In order to form a nanocoating capable of maintaining the newly assembled phage in a complete cell microenvironment, the present invention uses a dense and strong nanocoating based on L100-55 (methacrylic acid-ethyl acrylate copolymer). This nanocoating has the ability to block the penetration of protons and medium-related substances. After treatment with the nanocoating, the surface Zeta potential of Salmonella increased from -6.79±1.16mV to -1.51±0.73mV ( Figure 2 e). The formation of the entire nanocoating was confirmed by labeling the copolymer with Cy3. The observation results showed that each Salmonella cell infected with Cy5.5-labeled N1 phage exhibited a complete fluorescent shell ( Figure 2f). Transmission electron microscopy imaging showed that a continuous nanocoating structure was formed on the bacteria ( Fig.10 a). Flow cytometric analysis showed that the fluorescence signal of bacteria increased significantly after being coated with the Cy3-labeled copolymer ( Fig.10 be). Quantitative analysis showed that the coating efficiency was as high as 93.7% ( Fig.10 d, e). In the absence of nanocoating treatment, the fluorescence signal in the mCherry-expressing Salmonella cells was limited, suggesting the release of intracellular substances. However, after the nanocoating was applied, significant mCherry signals were observed in the infected Salmonella cells, confirming the retention of bacterial integrity ( Fig.11 ).
[0118] Example 2: Intact phage exhibits high activity during amplification
[0119] The activity of latent phages was systematically evaluated in this example. Salmonella infected with N1 phages that were not coated with nanocoatings (defined as Ex-phages) were used as controls. Accordingly, latent phages obtained from Salmonella modified with nanocoatings were called In-phages. After 36 hours of culture in 10mM PBS at 37°C, the titer of Ex-phages decreased by about 18 times. In contrast, In-phages continued to proliferate under these conditions, indicating the beneficial effects of the intracellular microenvironment on maintaining phage activity ( Figure 3 a). In fact, the assembly of phages in a bacteria-free system based on bacterial extracts has been reported previously. We then cultured the Ex-phages and In-phages in different culture media, including Luria-Bertani (LB) medium, salt magnesium (SM) buffer, and saline, at 37 °C for 0, 5, 10, 24, and 36 h to ensure that the results were not affected by specific culture media or temperature conditions. It is worth noting that there was no obvious deviation in the titer changes of In-phages in different culture media environments ( Figure 3 a, b). The increase in the number of phages is attributed to the continuous assembly of phages inside the bacteria coated with the nanocoating. After 9 hours of incubation, the assembly of in-phages reached a plateau ( Fig.12 We found that the titers of In-phages were always significantly higher than those of Ex-phages in LB, SM buffer, and saline ( Figure 3ce). At the same time, under these conditions, the titer of Ex-phages decreased rapidly with increasing incubation time. These differences in phage activity verified the sensitivity of Ex-phages to the external environment, revealing that phages collected according to normal procedures are inevitably damaged and have reduced activity compared to latent phages. In addition, we observed that In-phages showed increased resistance to different temperatures including 4°C, 50°C, and 70°C compared to Ex-phages ( Figure 3 fh). In particular, after 72 h of incubation at 4°C, the titer of In-phages remained almost unchanged, whereas the titer of Ex-phages dropped dramatically by about 34-fold under the same conditions. To explore whether the observed high activity of In-phages exists in other types of phages, we evaluated the activity of In-phages obtained from Gram-negative Pseudomonas aeruginosa and Gram-positive Staphylococcus aureus. As in Figure 3 As verified in i and j, In-phages maintained higher titers than Ex-phages at different culture time points. In summary, with the help of nanocoating, we found that latent phages showed superior activity during amplification than phages released and exposed to the external environment.
[0120] Example 3: Superior capabilities of In-phages in bacterial inhibition and biofilm removal
[0121] After confirming that they have higher activity than Ex-phages, we next examined whether In-phages have more outstanding bactericidal properties. The adsorption of phages to host bacteria is the initial step in their antibacterial effect. Therefore, this study first measured the binding efficiency of In-phages to host bacteria. The study found that compared with Ex-phages, In-phages have a superior ability to bind to host Salmonella cells at different infection multiplicity values ( Figure 4 a). At an MOI of 0.1, the binding rate of In-phages was 1.25 times higher than that of Ex-phages. When the MOI was reduced to 0.01 or 0.001, the difference further increased to about 3.00 times. At the same time, when infected with Salmonella at an MOI of 0.1, In-phages reached a plateau state within 3 minutes, which was 10 times faster than Ex-phages ( Fig.13 a). It is noteworthy that In-phages lysed more than 50% of Salmonella within 10 minutes, while Ex-phages achieved similar bactericidal effects only after a prolonged incubation time of 30 minutes ( Figure 4b). Notably, In-phages targeting Pseudomonas aeruginosa or Staphylococcus aureus also showed significant ability in binding and inhibiting the corresponding host cells ( Figure 4 cf and Fig.13 b, c). It is well known that bacteria become resistant and drug-resistant under the protection of biofilms, and are resistant to both antibiotics and immune responses, which represents a major clinical problem. In view of this fact, we further measured the clearance effect of In-phages on biofilms. Salmonella carrying green fluorescent protein was cultured in LB medium for 4 days to form a biofilm. Then, In-phages and Ex-phages labeled with Cy5.5 were added respectively. Obviously, as shown by the red fluorescent signal (Cy5.5-labeled phage), the penetration effect of In-phages was able to effectively kill Salmonella expressing green fluorescent protein within the biofilm after 60 minutes of co-culture ( Figure 4 g). As the incubation time was extended to 90 minutes, the disappearance of green fluorescence indicated that the bacteria were almost eliminated. In contrast, the biofilm co-cultured with Ex-phages still maintained a clear green fluorescence signal even when the incubation time was extended to 90 minutes, indicating that the effect of removing the biofilm was weakened ( Figure 4 h). In addition, crystal violet staining experiments showed that in different incubation concentration ranges (5×10 7 Up to 5×10 11 Plaque forming units (PFU / mL), In-phages were more effective than Ex-phages in clearing Salmonella biofilm ( Figure 4 i). After a relatively short incubation period of 30 minutes, In-phages were able to exhibit significantly improved biofilm removal efficiency, showing a faster removal rate for Salmonella biofilm ( Figure 4 j). To examine whether this superior ability applies to other types of In-phages, we compared the effectiveness of specific In-phages of Pseudomonas aeruginosa (Pseudomonas aeruginosa), a pathogen that forms biofilms and causes a variety of chronic infections, in removing biofilms. In-phages of Pseudomonas aeruginosa also showed higher efficiency in removing formed biofilms compared to corresponding Ex-phages, even at 5 × 10 2 PFU / mL at low feeding concentration ( Figure 4 k, l). In summary, in addition to having superior activity, In-phages were also superior to Ex-phages in binding and killing host bacteria and clearing bacterial biofilms.
[0122] Example 4: In-phages maintain high activity in vivo
[0123] The sensitivity of phages to the in vivo environment is another major reason for the limited efficacy of phage therapy. For example, oral administration, the most popular route of drug delivery, suffers from extremely low phage bioavailability. Therefore, it is crucial to maintain high phage viability at the in vivo site of interest. We investigated the viability of In-phages in the intestine after oral ingestion, considering the shielding effect of nanocoatings that can protect In-phages from gastric acid. We first investigated the on-demand release of latent phages in the intestine. Figure 5 As shown in a and b, the fluorescent signal of Cy5.5-labeled phages appeared along the intestine, which was different from that of Cy3 copolymers labeled 30 minutes after ingestion, supporting the view that phages were released from host bacterial cells. In addition, the intestinal distribution of In-phages surviving in the intestine was evaluated by measuring the number of In-phages in different intestinal segments of the digestive tract. Oral In-phages showed uneven distribution in various gastrointestinal tract regions. After oral administration at different time points, most of the surviving phages were distributed in the intestine, rather than the stomach ( Fig.14 ad). In particular, more than 90% of the surviving phages were located in the intestine at 60, 150, and 210 min after oral ingestion ( Fig.14 eh). Notably, both the jejunum and colon presented the highest phage abundance, accounting for approximately 40% of the total surviving phages, further illustrating the selective release of In-phages in the intestine. This result is consistent with the results of fluorescent live imaging of Cy5.5-labeled phages in the intestine. According to calculations, the fluorescence intensity of the intestine in the In-phages group was 2.12 times higher than that in the Ex-phages group 1 hour after oral administration ( Figure 5 c, d). This result verifies that the bioavailability of oral In-phages is significantly improved. We further measured the titer of phages in the intestine and found that few surviving phages were detected in the Ex-phages group, which is consistent with previous studies that orally administered phages can hardly survive in an acidic environment. In contrast, there were approximately 1×10 7 PFU of viable phages are retained in the intestine ( Figure 5 e, f). By using the specific fluorescent dye Alexa Fluor 633-conjugated concanavalin A (Alexa Fluor 633-ConA), we found that In-phages, but not other groups, showed the ability to clear Salmonella biofilm ( Figure 5g). The extreme differences in the number of viable phages were attributed to the pH-triggered selective release of In-phages in the gut. Given the marked reduction in phage activity after release from host bacterial cells, we believe that on-demand release of latent phages at sites of interest could provide a viable approach for phage therapy.
[0124] Example 5: Mechanism behind the super vigor of latent phage
[0125] Given that the activity of phages is closely related to the integrity of their structure (Kauffman, KM et al. Resolving the structure of phage–bacteria interactions in the context of natural diversity. Nat Commun. 13, 372 (2022).), we first observed the morphology of N1 phage using cryo-electron microscopy. Figure 6 As shown in a and b, the long tail consists of an adsorption device (tip) and a tube. The tail and the capsid (head) are connected by a head-to-tail connector. In both ex-phages and in-phages, there is a fork-shaped structure at the end of the tail ( Figure 6 c, left). To reveal the structural differences between the two phages, we performed subtomographic averaging of their tips. Three-dimensional classification revealed that both tip structures exhibit C3 symmetry ( Figure 6 c, right). Local resolution estimates show that the tips of Ex-phages and In-phages adopt flexible structures ( Fig.15 ). Comparing the phage tips, it can be found that the terminal density of Ex-phages is missing compared with In-phages ( Figure 6 d). It is calculated that the length of the Ex-phage tip is about 3.6nm shorter than that of the In-phages ( Figure 6d). These results indicate the absence of tail-related functional proteins. Considering that tail proteins are responsible for the specificity and virulence of phages (Zampara, A. et al. Exploiting phage receptor binding proteins to enable endolysins to kill Gram-negative bacteria. Sci Rep. 10, 12087 (2020); Brzozowska, E., Bazan, J. & Gamian, A. The functions of bacteriophage proteins. Postepy Hig Med Dosw (Online). 65, 167-176 (2011).), we further detected the differences in functional proteins between In-phages and Ex-phages by proteomics ( Fig.16 a). Sodium dodecyl sulfate polyacrylamide gel electrophoresis showed that the tail protein of Ex-phages was significantly degraded compared with In-phages ( Fig.16 b). The principal component analysis of the phage proteome sequence data showed that the Ex-phages and In-phage clusters formed an independent cluster, confirming the reliability of the acquired sequence data ( Fig.17 a). In addition, cluster analysis showed that there were significant differences in protein abundance between In-phages and Ex-phages ( Figure 6 e,f). The Venn diagram was used to further compare the changes in the proteome. Fig.17 b The results showed that there were 312 overlapping differentially expressed proteins between Ex-phages and In-phages, and 6 and 13 uniquely expressed proteins in Ex-phages and In-phages, respectively. By excluding non-characterized proteins, we found that 9 proteins were downregulated in Ex-phages compared with In-phages ( Fig.17c). Among them, three proteins (including carrier domain protein, tail sheath protein and lytic protein A) are closely related to phage invasion. The carrier domain protein guides the external interaction of host bacterial surface receptors (Crosby, J. & Crump, MP The structural role of the carrier protein-active controller or passive carrier. Nat Prod Rep. 29, 1111-1137 (2012).). After recognition, the conformational change of the tail sheath protein promotes the injection of genetic material from the phage into the host cell (Kreitz, J. et al. Programmable protein delivery with a bacterial contractile injection system. Nature. 616, 357-364 (2023).). Lytic protein A triggers the formation of membrane adhesion sites between the inner and outer membranes, leading to bacterial lysis (Rodwell, EV et al. Isolation and characterization of bacteriophages with activity against invasive non-typhoidal Salmonella causing bloodstream infection in Malawi. Viruses. 13, 478 (2021).;) Paradiso, R et al. Complete genome sequences of three Siphoviridae bacteriophages infecting Salmonella enterica serovar Enteritidis. Genome Announc. 4, e00939 (2016).). Strikingly, the levels of these proteins in In-phages were 1.52-fold, 2.54-fold, and 3.56-fold higher than those in Ex-phages ( Figure 6 gi). We also identified the altered sites by peptide analysis. In the vector domain-containing proteins, FDNIDDNIDALAPLR was between 36 and 50 residues, and MSNKPTYVEVMR was between 1 and 12 residues. The relative abundance of the two amino acid sequences was about 4 times higher in In-phages ( Figure 6 jm). Note that the FDNIDDNIDALAPLR sequence was not detected in the Ex-phages ( Figure 6 k). Similarly, the VFAVLNQFR (482-490 residues) sequence of the tail sheath protein ( Figure 6 n,o) and cleavage protein A AAMDSAHGDISSGDWVR ( Figure 6 p,q) sequence ( Figure 6 p,q) were also significantly reduced in Ex-phages. In addition, co-occurrence network analysis of the relative abundance of Ex-phages and In-phages proteins showed that the reduced expression of tail sheath protein and lytic protein A was associated with the upregulation of proteins related to DNA replication and repair ( Fig.17 d). In particular, the expression of caudal sheath protein was negatively correlated with DNA ligase (coefficient = -0.94, p < 0.01, Fig.17 e). At the same time, the expression of lytic protein A decreased and DNA helicase (coefficient = -0.89, p < 0.05, Fig.17 f) and ribonucleoside diphosphate reductase (coefficient = -0.90, p < 0.01, Fig.17 These data suggest that the reduction in activity of phages after they are released from host bacterial cells and subjected to environmental damage is caused by the hydrolysis of phage tail proteins, which play an important role in infecting host bacterial cells.
[0126] Example 6: Therapeutic value of in-phages in treating pathogen infection and related arthritis
[0127] After confirming the excellent activity of In-phages, we further explored the therapeutic value of In-phages in the treatment of intestinal infections and infectious arthritis. 5 The mouse model of intestinal infection was established by oral gavage of 5×10 Salmonella colony-forming units (CFU). 7 PFU for 9 days), and daily quantification of Salmonella and N1 phages was performed in fecal samples. Infected mice were orally treated with PBS, Pure-phages (N1 collected by standard phage propagation and purification procedures), or Ex-phages as controls ( Fig.18 a). After 5 days of In-phages treatment, a significant decrease in the number of Salmonella was observed, indicating a sustained inhibitory effect of In-phages on Salmonella, while Pure-phages and Ex-phages did not show similar effects ( Fig.18 b). Consistent with the abundance in feces, the number of Salmonella in the intestines of In-phages-treated mice was lower than that of the control group ( Figure 7 a). The elimination of Salmonella was further confirmed by staining with a Salmonella O antibody ( Fig.18c). Compared with the In-phages group, the figure shows little fluorescence signal. Correspondingly, the effective elimination of Salmonella in the In-phages group increased the titer of N1 phage in feces and intestines ( Fig.18 d,e and Figure 7 b). In-phages effectively inhibited Salmonella and protected the intestine from damage, while the intestinal tissue of mice treated with Pure-phages or Ex-phages still had pathological damage to the muscular layer ( Figure 7 c). Successful elimination of Salmonella from the intestine avoids abnormal immune responses caused by Salmonella translocation ( Figure 7 df). The inflammatory cytokines interleukin-6 and tumor necrosis factor-α in serum and Salmonella translocation were reduced in the In-phages group compared with all other groups. In short, oral In-phages demonstrated the potential to inhibit enteric pathogens and reduce inflammatory responses as well as pathogen translocation.
[0128] Pathogen infection has been identified as a potential trigger for autoimmune responses leading to rheumatoid arthritis. The presence of biofilm components, such as curli protein, can lead to intestinal barrier dysfunction and the accumulation of anti-double-stranded DNA antibodies, ultimately leading to autoimmune dysregulation. As intestinal infection progresses, PBS-treated mice develop severe lesions in the third metacarpophalangeal joint compared with healthy mice ( Figure 7 g). No obvious lesions were found in the ankle joint ( Fig.19 a, b). This indicates that the pathological process of Salmonella-induced rheumatoid arthritis is mainly confined to the finger joints of mice. The third metacarpophalangeal joint of mice treated with In-phages was structurally intact, while mice in the Pure-phages and Ex-phages groups had pathological changes. In addition, In-phages treatment reduced synovial hypertrophy and hyperplasia, while reducing the thickness of the synovial cell layer ( Fig.19 c). These findings suggest that in-phages have therapeutic potential in Salmonella-induced infection-related arthritis. Effective inhibition of the pathogen protected the intestine from damage, as evidenced by less pathological changes and less inflammatory cell infiltration ( Fig. 20 ). In-phages treatment significantly protected the intestinal barrier, and the expression levels of tight junction proteins ZO-1 and Occludin did not change significantly ( Fig.21 a). Alcian blue-nuclear fast red staining further showed the intact mucus layer of intestinal tissue of In-phages ( Fig.21 b). It is worth mentioning that the protection of the intestinal barrier eliminates the accumulation of anti-double-stranded DNA in plasma ( Figure 7h). Flow cytometry analysis results showed that In-phages treatment effectively inhibited the increase in interleukin-17 levels caused by abnormal T helper cell 17 polarization ( Figure 7 i, j). Recent reports have shown that IL-17-producing Th17 cells can mediate arthritis during Salmonella infection. In addition, in-phages can effectively promote mucosal immune responses, as shown by increased levels of B cells that produce immunoglobulin A, which has the function of clearing pathogenic microorganisms ( Figure 7 k). These results demonstrate the therapeutic potential of In-phages, whose intervention in rheumatoid arthritis benefits from their high activity, which effectively removes pathogenic biofilms and prevents intestinal barrier damage.
[0129] Example 7: Safety of In-phages
[0130] The safety of In-phages was systematically evaluated in vivo. In the experiment, mice were orally administered PBS, Pure-phages, Ex-phages, and In-phages ( Fig. 22 Comparative analysis showed that the body weight of mice orally treated with In-phages showed little fluctuation and was comparable to that of mice treated with PBS and mice treated with Pure-phages ( Figure 8 a) Complete inactivation of phage-infected bacteria is crucial for the safety of in-phage-mediated therapy. Fig.23 As shown, no live Salmonella was detected in the intestine, indicating that oral administration of In-phages avoided potential infection caused by phages. Increases in leukocytes and neutrophils usually occur after bacterial infection. In contrast, decreased neutrophil levels are associated with viral infection. In addition, viral infection can lead to increased lymphocyte counts. Therefore, we further measured changes in routine blood tests and blood biochemical parameters of mice. Consistent with the results that no Salmonella was detected in the intestine, the levels of leukocytes and neutrophils in the In-phage group were similar to those in the PBS and Pure-phages groups ( Figure 8 b, c). As Figure 8 d, e and Fig.24 As shown in Figure ac, other hematological parameters including lymphocytes, hemoglobin, erythrocytes, platelets, and eosinophils did not change significantly. Similarly, the blood biochemical parameters of mice treated with In-phages (creatine kinase isoenzymes and lactate dehydrogenase in heart function, aspartate aminotransferase and alkaline phosphatase in liver function, creatinine and blood urea nitrogen in kidney function) were similar to those of mice treated with PBS ( Figure 8 fh and Fig.24df). In addition, H&E staining evaluation of ileum, colon, heart, liver, spleen, lung, and kidney tissues showed no pathological changes in the In-phage group compared with the PBS control group ( Figure 8 i). These results suggest that oral administration of In-phages exhibits a favorable safety profile in phage therapy of enteric infections.
[0131] in conclusion
[0132] The present invention adopts a single bacteria nanotechnology that can artificially manipulate the lysis process of infected host bacteria. We found that before being released into the external environment, the activity of the newly assembled phage in the bacteria is significantly higher than that after release. This nanotechnology can form an entire polymer nanocoating on a single bacterium invaded by phages after bacterial lysis, which can not only prevent the phage from being exposed to the unfriendly external environment after bacterial lysis, but also retain the internal microenvironment of the bacteria to maintain the integrity of the phage. The latent phages thus produced retain their superior ability to amplify, bind and lyse specific bacteria and remove the corresponding bacterial biofilm. The present invention reveals that the reduced activity of the released phages is attributed to the damage of the phage structure, especially the severe degradation of key tail proteins including carrier domain proteins, tail sheath proteins and lysis protein A. In addition, by circumventing the damaging factors associated with phage production and in vivo delivery, a stimuli-responsive nanocoating is used to selectively release intact phages in the part of interest after the lysis of the host bacteria, thereby maintaining the high activity of the phages. Compared with traditional phage therapy, the results of the present invention show that the in situ release of latent phages triggered by pH in the intestine with the help of nano-coating can significantly improve the bioavailability of phages, thereby showing outstanding therapeutic effects in treating intestinal infections and related arthritis in mice. At the same time, the present invention also provides new insights into the activity and potential mechanisms of phages and provides an alternative nano-platform for phage therapy.
[0133] The above description is only a preferred embodiment of the present invention and is not any formal or substantial limitation of the present invention. It should be pointed out that a person skilled in the art can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention.
Claims
1. A method for preparing latent bacteriophage based on nano-coating, characterized in that: The following steps are involved: Step 1: The host bacteria are cultured and separated to obtain bacterial cells, and the bacterial cells are infected with bacteriophages in the culture medium to obtain cells infected with bacteriophages; Step 2: Place cells infected with phage in a solution of Ca 2+ The nanoparticles are incubated in a solution of nanomaterials by shaking to form a nanocoating, washed, and centrifuged to collect the precipitate, thereby obtaining latent phages coated with the nanocoating.
2. The method according to claim 1, characterized in that The nanomaterial in step 2 is a polymer nanomaterial.
3. The method according to claim 1, characterized in that In order to form a single nanocoating on each bacterial cell, when the bacterial cells are infected with bacteriophages in the culture medium in step 1, the infection multiplicity is 100 and the infection time is 15 minutes.
4. Use of the method according to any one of claims 1 to 3 in preparing a latent bacteriophage coated with a stimulus-responsive nanocoating, characterized in that: The nanomaterials used are stimuli-responsive polymers.
5. The use according to claim 3, characterized in that The stimulus responsive polymer is a pH responsive polymer.
6. The use according to claim 5, characterized in that The pH responsive polymer is a methacrylic acid-ethyl acrylate copolymer.
7. A method for preparing a latent phage capable of being specifically released in the intestine, characterized in that: The following steps are involved: Step 1: The host bacteria are cultured and separated to obtain bacterial cells, and the bacterial cells are infected with bacteriophages in the culture medium to obtain cells infected with bacteriophages; Step 2: Phage-infected cells are cultured in a solution containing gut-responsive polymers and Ca 2+ The intestinal responsive polymer is incubated in a solution of 5% ethanol and / or 1% sodium bicarbonate to form a nanocoating, washed, and centrifuged to collect the precipitate, thereby obtaining latent phages coated with the nanocoating; the intestinal responsive polymer is an enteric polymer and / or a polymer that responds to the intestinal pH value.
8. Use of the latent bacteriophage prepared by the method according to any one of claims 1 to 4 in the preparation of antibacterial products.
9. Use of the latent bacteriophage prepared by the method according to any one of claims 1 to 4 in the preparation of biological products for treating pathogen infectious diseases and pathogen infection-related arthritis.
10. Use of the latent phage prepared by the method of claim 7 in the preparation of a biological product for treating enteric Salmonella infection and related arthritis, characterized in that: The related arthritis refers to arthritis induced by intestinal Salmonella infection, and the latent phage is a Salmonella phage.
